“Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.” Is dPCR the key?-Reference-Cited by-同舟云学术

“Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.” Is dPCR the key?

Published:2019-07-07 Issue:3 Volume:103 Page:272-273
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Bernardi Simona¹²^ORCID,Bonifacio Massimiliano³^ORCID,Iurlo Alessandra⁴,Zanaglio Camilla¹²,Tiribelli Mario⁵,Binotto Gianni⁶,Abruzzese Elisabetta⁷^ORCID,Russo Domenico¹

Affiliation:

1. Unit of Blood Diseases and Stem Cell Transplantation, DPT of Clinical and Experimental Sciences University of Brescia, ASST Spedali Civili di Brescia Brescia Italy

2. CREA Laboratory (Centro di Ricerca Emato‐Oncologica AIL) ASST Spedali Civili di Brescia Brescia Italy

3. Department of Medicine, Section of Hematology University of Verona Verona Italy

4. Hematology Division Foundation IRCCS Ca' Granda‐Ospedale Maggiore Policlinico Milan Italy

5. Division of Hematology and Bone Marrow Transplantation, Department of Medical Area University of Udine Udine Italy

6. Department of Medicine, Hematology and Clinical Immunology University of Padua Padua Italy

7. Division of Hematology S. Eugenio Hospital Roma Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13282

Reference8 articles.

1. Variant‐specific discrepancy when quantitatingBCR‐ABL1e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay

2. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

3. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

4. Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC;Bonifacio M;Blood,2015

5. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-20

2. Variant‐specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia;International Journal of Laboratory Hematology;2024-06-05

3. Failure of Treatment-Free Remission after a Prolonged Deep Molecular Response in Patients with Chronic Myeloid Leukemia;Acta Haematologica;2024-04-04

4. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements;Blood Cancer Journal;2024-03-26

5. Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?;Cancers;2024-02-20